TY - JOUR
T1 - Lenalidomide in multiple myeloma: current status and future potential
AU - Quach, Hang
AU - Kalff, Anna
AU - Spencer, Andrew
PY - 2012
Y1 - 2012
N2 - The clinical development of lenalidomide (Revlimid?), then pomalidomide (Actimid?) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents. Increased experience and understanding of IMiD s diverse biological effects has lead to rational design of lenalidomide-based treatment-regimens over recent years. However, much about lenalidomide is yet to be understood and fully exploited. Here, we review what is known of lenalidomide s biological effects, clinical certainties and uncertainties in the treatment of MM, and explore its future potential with other synergistic therapeutic agents. ? 2012 Wiley Periodicals, Inc.
AB - The clinical development of lenalidomide (Revlimid?), then pomalidomide (Actimid?) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents. Increased experience and understanding of IMiD s diverse biological effects has lead to rational design of lenalidomide-based treatment-regimens over recent years. However, much about lenalidomide is yet to be understood and fully exploited. Here, we review what is known of lenalidomide s biological effects, clinical certainties and uncertainties in the treatment of MM, and explore its future potential with other synergistic therapeutic agents. ? 2012 Wiley Periodicals, Inc.
UR - https://www.scopus.com/pages/publications/84869163369
U2 - 10.1002/ajh.23234
DO - 10.1002/ajh.23234
M3 - Article
SN - 0361-8609
VL - 87
SP - 1089
EP - 1095
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 12
ER -